米诺环素治疗急性脑出血的早期随机试验
这项单中心随机对照试验纳入16例原发性脑出血患者,8例接受米诺环素400mg静脉后400mg口服每日4天。米诺环素安全且达到神经保护血药浓度,但口服吸收延迟,Tmax至少6小时,炎症标志物、血肿体积和血肿周围水肿无差异。
要点
- 米诺环素400mg静脉后口服在脑出血患者中安全,可达到神经保护浓度。
- 口服米诺环素在危重患者中吸收延迟,Tmax至少6小时,不适合需快速高浓度时。
- 米诺环素对炎症标志物、血肿体积和血肿周围水肿未见显著影响。
核心结论
- 米诺环素400mg在脑出血中安全且达到神经保护血清浓度,但口服吸收延迟。
研究设计与样本
- 单中心随机对照试验,2013至2016年纳入16例成人原发性脑出血患者,8例随机至米诺环素组。
主要发现
- 米诺环素组口服后Tmax估计至少6小时,消除半衰期17.5小时(SD±3.5)。
- 炎症标志物、血肿体积和血肿周围水肿未见差异。
- 7例中5例在给药间期维持神经保护浓度(>3 mg/L)。
关键数值与推荐
- 米诺环素用法为静脉400mg后口服400mg每日4天。
- 神经保护浓度定义为>3 mg/L。
- 口服米诺环素文献Tmax为1小时,但本队列Tmax至少6小时。
临床怎么用
- 脑出血患者如需快速达到高浓度,不应使用口服米诺环素。
- 静脉米诺环素可作为院前治疗试验的候选药物。
局限性
- 单中心小样本研究,仅16例患者。
- 半衰期数据仅来自7例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Minocycline is under investigation as a neurovascular protective agent for stroke. This study evaluated the pharmacokinetic, anti-inflammatory, and safety profile of minocycline after intracerebral hemorrhage. METHODS: This study was a single-site, randomized controlled trial of minocycline conducted from 2013 to 2016. Adults ≥18 years with primary intracerebral hemorrhage who could have study drug administered within 24 hours of onset were included. Patients received 400 mg of intravenous minocycline, followed by 400 mg minocycline oral daily for 4 days. Serum concentrations of minocycline after the last oral dose and biomarkers were sampled to determine the peak concentration, half-life, and anti-inflammatory profile. RESULTS: A total of 16 consecutive eligible patients were enrolled, with 8 randomized to minocycline. Although the literature supports a time to peak concentration (Tmax) of 1 hour for oral minocycline, the Tmax was estimated to be at least 6 hours in this cohort. The elimination half-life (available on 7 patients) was 17.5 hours (SD±3.5). No differences were observed in inflammatory biomarkers, hematoma volume, or perihematomal edema. Concentrations remained at neuroprotective levels (>3 mg/L) throughout the dosing interval in 5 of 7 patients. CONCLUSIONS: In intracerebral hemorrhage, a 400 mg dose of minocycline was safe and achieved neuroprotective serum concentrations. However, oral administration led to delayed absorption in these critically ill patients and should not be used when rapid, high concentrations are desired. Given the safety and pharmacokinetic profile of minocycline in intracerebral hemorrhage and promising data in the treatment of ischemic stroke, intravenous minocycline is an excellent candidate for a prehospital treatment trial. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01805895.
引用
- Fouda AY, Newsome AS, Spellicy S, et al. Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. Stroke. 2017. PMID: 28887388. doi:10.1161/STROKEAHA.117.018658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。